Testosterone Replacement Therapy (TRT): The Complete Guide

Overview

Testosterone is the primary androgen hormone in the human body. It plays a central role in sexual development, muscle and bone maintenance, red blood cell production, fat distribution, mood regulation, and cognitive function. In males, testosterone is produced primarily by the Leydig cells of the testes under the control of luteinizing hormone (LH) from the pituitary gland. Smaller amounts are produced by the adrenal glands in both sexes.

Testosterone levels naturally decline with age. Total testosterone decreases by approximately 1–2% per year after age 30 in males (Harman et al., 2001). When levels fall below the physiological range — generally considered below 300 ng/dL total testosterone by most laboratory reference standards — and symptoms are present, the condition is termed hypogonadism.

TRT restores circulating testosterone to the normal physiological range (typically 400–700 ng/dL) through exogenous administration. Multiple delivery systems are FDA-approved: intramuscular and subcutaneous injections of testosterone esters (cypionate, enanthate, undecanoate), transdermal gels and patches, nasal gels, and subcutaneous pellets. Each delivery method has distinct pharmacokinetics, cost profiles, and practical considerations.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with low testosterone, demonstrated improvements in sexual function, physical function, vitality, bone density, and anemia correction with one year of testosterone gel treatment (Snyder et al., 2016). These trials represent the largest body of randomized evidence for TRT in older men.

TRT suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone signals the hypothalamus and pituitary to reduce production of gonadotropin-releasing hormone (GnRH), LH, and follicle-stimulating hormone (FSH). This results in decreased endogenous testosterone production and, critically, reduced or absent spermatogenesis. TRT should not be used as monotherapy in males who wish to preserve fertility without concurrent measures such as human chorionic gonadotropin (HCG) co-therapy.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Androgen Receptor Activation

Testosterone exerts its effects primarily through binding to the androgen receptor (AR), a nuclear receptor present in virtually every tissue in the body. When testosterone binds to the AR, the receptor-hormone complex translocates to the cell nucleus and acts as a transcription factor, upregulating or downregulating the expression of hundreds of target genes. This genomic mechanism underlies the broad physiological effects of testosterone on muscle protein synthesis, bone mineral density, erythropoiesis, and sexual function (Bhasin et al., 2018).

Conversion to Active Metabolites

Testosterone serves as a prohormone for two additional active metabolites:

• Dihydrotestosterone (DHT): Produced by the enzyme 5α-reductase, DHT binds the androgen receptor with approximately 2–3 times greater affinity than testosterone. It is the primary androgen responsible for prostate growth, scalp hair follicle miniaturization (androgenetic alopecia), sebaceous gland activity, and external genital development.
• Estradiol (E2): Produced by the enzyme aromatase (CYP19A1), estradiol is the primary estrogen in males. It plays essential roles in bone density maintenance, lipid metabolism, brain function, and negative feedback on the HPG axis. Aromatization increases with body fat percentage, which is clinically relevant for monitoring estradiol levels during TRT.

HPG Axis Suppression

The hypothalamic-pituitary-gonadal axis operates as a negative feedback loop. Under normal physiology:

1. The hypothalamus releases GnRH in pulsatile fashion
2. GnRH stimulates the anterior pituitary to release LH and FSH
3. LH stimulates testicular Leydig cells to produce testosterone
4. FSH stimulates Sertoli cells to support spermatogenesis
5. Rising testosterone levels feed back to the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion

When exogenous testosterone is administered, it provides supraphysiological negative feedback, suppressing GnRH, LH, and FSH. This results in:

• Testicular atrophy: Without LH stimulation, Leydig cells reduce in size and number, and the testes decrease in volume
• Spermatogenesis suppression: Without FSH (and intratesticular testosterone produced by LH-stimulated Leydig cells), sperm production declines significantly or ceases entirely
• Dependence: Endogenous production may take weeks to months to recover after TRT discontinuation, and in some cases may not fully recover

Pharmacokinetics by Formulation

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

The Testosterone Trials (TTrials) — Snyder et al., 2016

The TTrials represent the most comprehensive randomized evidence for TRT in older men. This coordinated set of seven double-blind, placebo-controlled trials enrolled 790 men aged ≥65 years with serum testosterone below 275 ng/dL and symptoms of hypogonadism. Participants received testosterone gel (AndroGel 1%) or placebo for 12 months (Snyder et al., 2016).

Key findings across the seven component trials:

• Sexual Function Trial: Testosterone treatment significantly improved sexual desire, erectile function, and sexual activity compared to placebo
• Physical Function Trial: Modest improvement in walking distance (6-minute walk test); no significant improvement in other physical function measures
• Vitality Trial: Small but statistically significant improvement in self-reported vitality and mood (PHQ-9 depression scores)
• Bone Trial: Increased volumetric bone mineral density and estimated bone strength at the spine and hip
• Anemia Trial: Corrected unexplained anemia of aging in 58% of testosterone-treated men vs. 22% on placebo
• Cognitive Function Trial: No significant improvement in memory or cognitive function
• Cardiovascular Trial: Increased coronary artery plaque volume (noncalcified plaque) was observed — a finding that raised safety questions, though the trial was not powered to assess cardiovascular events

Dose-Response Relationships — Bhasin et al., 2018

Bhasin and colleagues conducted dose-response studies establishing the relationship between testosterone levels and physiological outcomes. Their work demonstrated that different outcomes have different testosterone thresholds: sexual function improvements require relatively modest testosterone increases, while muscle mass and strength changes require higher levels. Fat mass reduction occurs across a broad range of testosterone concentrations (Bhasin et al., 2018).

These findings have practical implications for dosing: targeting the mid-normal range (500–700 ng/dL) appears sufficient for most clinical endpoints, while supraphysiological levels do not proportionally increase benefits but do increase adverse effect risk.

Cardiovascular Safety — Corona et al., 2017

Cardiovascular safety has been the most debated aspect of TRT. A comprehensive meta-analysis by Corona et al. analyzed data from 75 randomized controlled trials (including 3,016 testosterone-treated and 2,448 placebo-treated men). The analysis found no increased risk of major adverse cardiovascular events (MACE) with testosterone treatment. In trials that excluded men at high cardiovascular risk, testosterone was actually associated with a reduced risk of cardiovascular events (Corona et al., 2017).

This meta-analysis was particularly important because it addressed concerns raised by two earlier studies — the TOM trial (2010) and a VA retrospective study (2013) — that had suggested increased cardiovascular risk with TRT. Those studies had significant methodological limitations that subsequent analyses have highlighted.

The TRAVERSE Trial

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) was a randomized, double-blind, placebo-controlled cardiovascular safety trial enrolling 5,246 men aged 45–80 with hypogonadism and preexisting or high risk of cardiovascular disease. Results demonstrated that testosterone treatment was noninferior to placebo for major adverse cardiovascular events, providing substantial reassurance regarding cardiovascular safety in this high-risk population (Lincoff et al., 2023).

Testosterone and Prostate Cancer — Morgentaler, 2009

For decades, the medical community operated under the assumption that testosterone fuels prostate cancer growth — a belief originating from Huggins and Hodges' 1941 Nobel Prize-winning observation that castration caused prostate cancer regression. Morgentaler's work challenged this paradigm with the "saturation model," which proposes that androgen receptors in prostate tissue become saturated at relatively low testosterone concentrations (~250 ng/dL). Above this saturation point, additional testosterone does not further stimulate prostate growth (Morgentaler, 2006).

Multiple observational studies and meta-analyses have since found no association between TRT and increased prostate cancer incidence. The Endocrine Society guidelines acknowledge that TRT does not appear to increase prostate cancer risk in men without a history of prostate cancer, though monitoring with PSA and digital rectal exam remains standard practice (Mulhall et al., 2018).

Women and Testosterone — Davis et al., 2019

A global consensus position statement led by Davis et al. systematically reviewed the evidence for testosterone therapy in women. The analysis found that testosterone, at doses approximating physiological male levels divided by 10 (i.e., producing female-range testosterone levels), demonstrated consistent benefits for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Evidence also supports potential benefits for bone density, body composition, and cognitive function, though data for non-sexual outcomes remains limited (Davis et al., 2019).

Limitations of the Research

• Study populations: Most large RCTs enrolled older men (≥65) with comorbidities. Data on younger hypogonadal men is more limited.
• Duration: Most trials lasted 6–12 months. Long-term safety data beyond 5 years is sparse.
• Fertility outcomes: Fertility suppression is well-documented but recovery after TRT discontinuation is variable and not fully studied in controlled settings.
• Women: Only one formulation (testosterone undecanoate, 40 mg) has received regulatory approval for women (in Australia), and no testosterone product is FDA-approved for women.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Male hypogonadism is the sole FDA-approved indication for testosterone replacement. Diagnosis requires both:

• Biochemical confirmation: Total testosterone below 300 ng/dL on at least two morning blood draws (testosterone follows a diurnal pattern with peak levels in the morning)
• Clinical symptoms: Reduced libido, erectile dysfunction, fatigue, decreased muscle mass or strength, increased body fat, depressed mood, decreased bone density, or anemia

Hypogonadism is classified as:

• Primary (testicular): The testes fail to produce adequate testosterone despite normal or elevated LH/FSH. Causes include Klinefelter syndrome, testicular injury or torsion, orchitis, chemotherapy/radiation, and cryptorchidism.
• Secondary (central): The hypothalamus or pituitary fails to produce adequate GnRH or LH/FSH. Causes include pituitary tumors, Kallmann syndrome, obesity, opioid use, and idiopathic hypogonadotropic hypogonadism.
• Late-onset (age-related): Gradual decline in testosterone associated with aging, often with features of both primary and secondary hypogonadism. This category is more controversial, and treatment is based on symptom burden and biochemical confirmation.

Clinical Applications

Women and Testosterone

Testosterone therapy in women is an area of growing clinical interest and evidence. Women produce testosterone from the ovaries and adrenal glands, and levels decline with age, particularly after menopause. The primary evidence-based indication in women is hypoactive sexual desire disorder (HSDD), where low-dose testosterone therapy has demonstrated consistent improvements in sexual desire, arousal, and satisfying sexual events in postmenopausal women (Davis et al., 2019).

Additional areas of clinical interest in women include:

• Energy and fatigue: Some evidence for improvement in vitality and reduced fatigue
• Bone density: Testosterone contributes to bone health in women; may be relevant for osteoporosis management
• Body composition: Potential benefits for lean mass maintenance in postmenopausal women
• Cognitive function: Limited and inconsistent data

No testosterone product is FDA-approved for use in women. Off-label prescribing uses compounded formulations at approximately one-tenth the male dose (typically 5–10 mg/day transdermal or equivalent). Monitoring for androgenic side effects (acne, hirsutism, voice deepening) is essential.

When TRT Is NOT Appropriate

• Fertility planning: TRT suppresses spermatogenesis. Males planning to conceive should not use TRT without concurrent fertility-preserving interventions (see Side Effects tab)
• Breast cancer or known prostate cancer: FDA-labeled contraindications
• Polycythemia (hematocrit >54%): TRT further increases red blood cell production
• Severe untreated sleep apnea: TRT may worsen obstructive sleep apnea
• Uncontrolled heart failure: Fluid retention risk
• Normal testosterone with nonspecific symptoms: TRT is not indicated for fatigue or low libido in the setting of normal testosterone levels

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Dosing by Formulation

Sources: FDA Depo-Testosterone (testosterone cypionate) Prescribing Information · Bhasin et al., 2018 — Endocrine Society Guidelines on Testosterone Therapy · Mulhall et al., 2018 — AUA Guidelines on Testosterone Deficiency

Delivery Method Comparison

Sources: Bhasin et al., 2018 — Endocrine Society Testosterone Therapy Guidelines · Bhasin et al., 2018 — Dose-response relationships in testosterone therapy

Dose Adjustment and Monitoring

Dosing is individualized based on:

• Trough testosterone levels: Blood drawn immediately before the next dose (for injectables) or in the morning (for gels/patches). Target: 400–700 ng/dL at trough.
• Clinical response: Symptom improvement in sexual function, energy, mood, and body composition
• Side effect monitoring: Hematocrit, estradiol, PSA, and lipid panel guide dose adjustments
• Estradiol management: If estradiol rises excessively (>40–50 pg/mL in males), dose reduction or aromatase inhibitor use may be considered

HCG Co-Therapy for Fertility Preservation

For males who wish to preserve fertility or prevent testicular atrophy while on TRT, human chorionic gonadotropin (HCG) is commonly co-prescribed. HCG mimics LH activity, maintaining intratesticular testosterone production and supporting spermatogenesis. Typical protocols involve 500–1,000 IU HCG administered subcutaneously 2–3 times per week alongside testosterone. This is an off-label use of HCG and should be managed by a provider experienced in male fertility (Mulhall et al., 2018).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What to Expect

Expected Timeline

Sources: Saad et al., 2011 — Onset of effects of testosterone treatment and time span until maximum effects · Snyder et al., 2016 — Testosterone Trials (TTrials): effects on sexual function, vitality, physical function · Bhasin et al., 2018 — Dose-response relationships and clinical endpoints

Factors Affecting Response

• Baseline testosterone level: Men with very low baseline levels (<200 ng/dL) typically experience more dramatic improvements than those with borderline levels (250–350 ng/dL)
• Age: Younger men tend to respond more robustly to TRT than older men, particularly for body composition and sexual function
• Body composition: Obese individuals may aromatize more testosterone to estradiol, potentially blunting response and requiring dose adjustment or aromatase inhibitor use
• Formulation: Stable-level formulations (gels, pellets, twice-weekly injections) may produce better symptom control than protocols with significant peak-to-trough fluctuation
• Lifestyle factors: Exercise (particularly resistance training), sleep quality, stress management, and nutrition significantly influence TRT outcomes
• Comorbidities: Diabetes, metabolic syndrome, and cardiovascular disease may moderate response to TRT

What TRT Does Not Do

• TRT does not produce supraphysiological muscle growth at replacement doses — it restores normal androgen levels, not bodybuilding-level hormones
• TRT does not cure the underlying cause of hypogonadism (except in cases where the cause is reversible, such as opioid-induced hypogonadism after opioid discontinuation)
• TRT does not reverse aging or serve as an anti-aging treatment, despite marketing claims to the contrary
• TRT does not reliably improve cognitive function based on current trial evidence

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects

Critical: Fertility Suppression and HCG Co-Therapy

HCG co-therapy is the primary strategy for preserving fertility during TRT. Human chorionic gonadotropin (HCG) mimics LH, maintaining intratesticular testosterone at levels sufficient to support spermatogenesis even while exogenous testosterone suppresses pituitary LH release. Typical protocols:

• Dose: 500–1,000 IU subcutaneously, 2–3 times per week
• Timing: Concurrent with TRT from the start of treatment
• Monitoring: Semen analysis every 3–6 months if fertility preservation is a goal
• Alternatives: Clomiphene citrate or enclomiphene (selective estrogen receptor modulators) may be used as TRT alternatives in younger men who prioritize fertility, as they stimulate endogenous testosterone production without suppressing spermatogenesis

Monitoring Schedule

Contraindications

• Breast cancer (male or female) — FDA-labeled contraindication
• Known or suspected prostate cancer — FDA-labeled contraindication
• Hematocrit >54% (polycythemia) — increased thromboembolic risk
• Severe untreated obstructive sleep apnea
• Uncontrolled heart failure
• Desire for near-term fertility without HCG co-therapy
• Pregnancy — teratogenic (virilization of female fetus)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA-Approved Formulations

Schedule III Classification

Testosterone and its esters are classified as Schedule III controlled substances under the U.S. Controlled Substances Act. This classification reflects the potential for abuse and dependence associated with anabolic-androgenic steroids. Regulatory implications include:

• Prescription requirement: A valid prescription from a licensed provider with DEA registration is required
• Refill limitations: Schedule III prescriptions may be refilled up to 5 times within 6 months of the original prescription date
• Record-keeping: Pharmacies must maintain records of all testosterone dispensing
• Possession without prescription: Illegal; subject to federal and state criminal penalties
• Importation: Personal importation of testosterone from international sources without a prescription is illegal

FDA Boxed Warning

Testosterone products carry an FDA-required boxed warning (the most serious type of drug warning) regarding:

• Secondary exposure: Women and children exposed to testosterone gel through skin contact may experience virilization (deepening of voice, abnormal hair growth, enlarged clitoris in females, precocious puberty in children). Products must be applied to covered skin areas and hands washed after application.
• Aveed-specific: Risk of pulmonary oil microembolism (POME) and anaphylaxis. Administration must occur in a healthcare setting with 30-minute post-injection observation.

Compounding

Testosterone is available through compounding pharmacies in addition to commercially manufactured products. Compounded testosterone is commonly used for:

• Custom dosing not available in commercial products
• Combined formulations (e.g., testosterone with anastrozole)
• Alternative delivery vehicles (e.g., cream vs. gel)
• Cost reduction compared to brand-name products

Compounded testosterone is not subject to the same FDA review and approval process as commercially manufactured products. Quality and consistency depend on the compounding pharmacy's adherence to USP standards.

WADA Status

Testosterone is prohibited by the World Anti-Doping Agency under Section S1 (Anabolic Androgenic Steroids) at all times. Therapeutic Use Exemptions (TUEs) for testosterone are generally not granted for male athletes, as WADA guidelines state that testosterone deficiency in athletes should be managed without exogenous testosterone when possible.

International Regulatory Variation

Testosterone is a controlled or prescription-restricted substance in most countries. Regulatory frameworks vary:

• United Kingdom: Prescription-only medicine (POM); not a controlled substance under the Misuse of Drugs Act (though anabolic steroids in general are Class C)
• Canada: Schedule IV controlled substance; prescription required
• Australia: Schedule 4 (prescription only); androgen therapy in women approved (testosterone undecanoate 40 mg — the only country with a female-approved product)
• European Union: Prescription required; Nebido (testosterone undecanoate) widely prescribed

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Monthly Cost by Formulation

Insurance Coverage

Unlike many non-FDA-approved treatments, TRT is generally covered by insurance when prescribed for documented hypogonadism. Coverage considerations:

• Generic injectables: Widely covered with low copays ($5–$30). Most insurance plans cover testosterone cypionate and enanthate without prior authorization.
• Brand-name products: May require prior authorization, step therapy (trying a cheaper formulation first), or have higher tier copays.
• Gels and patches: Coverage varies; generic gels are increasingly covered, but brand products (AndroGel, Androderm) may require prior authorization.
• Newer formulations (Aveed, Natesto, oral products): Often require prior authorization and may not be covered by all plans.
• Lab monitoring: Generally covered as part of endocrine or primary care management.
• HCG co-therapy: Insurance coverage for HCG is variable and has become more complex following FDA regulatory changes affecting compounded HCG.

Additional Costs

• Supplies (injectables): Syringes, needles, alcohol swabs — approximately $5–$15/month if self-administering
• Provider visits: Initial evaluation and follow-up appointments — $100–$300 per visit (may be covered by insurance)
• Laboratory monitoring: CBC, testosterone, estradiol, PSA, lipid panel — $100–$400 per lab draw without insurance; typically covered with insurance
• HCG (if prescribed): $50–$200/month depending on source and formulation
• Ancillary medications: Anastrozole (aromatase inhibitor, if needed) — $10–$30/month generic

Cost Optimization Strategies

• Generic testosterone cypionate injection is the most cost-effective TRT formulation by a significant margin
• Multi-dose vials are more economical than single-dose formats
• GoodRx and manufacturer discount programs can reduce out-of-pocket costs for brand products
• Compounding pharmacies may offer competitive pricing for customized formulations
• Telemedicine TRT clinics typically charge $100–$200/month all-inclusive (consultation, labs, medication, shipping)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Does TRT cause prostate cancer?

Answer: Current evidence does not support an association between TRT and increased prostate cancer risk. The historical concern originated from Huggins and Hodges' 1941 observation that castration caused prostate cancer regression, leading to the assumption that testosterone promotes prostate cancer. Morgentaler's saturation model demonstrated that androgen receptors in prostate tissue become saturated at testosterone levels around 250 ng/dL — below the normal range. Raising testosterone from hypogonadal to normal levels does not appear to further stimulate prostate growth (Morgentaler, 2006). Multiple meta-analyses and the TRAVERSE trial have found no increased prostate cancer incidence with TRT (Lincoff et al., 2023). However, TRT remains contraindicated in men with known or suspected prostate cancer, and PSA monitoring during treatment is standard practice.

Question: Does TRT cause heart attacks?

Answer: The TRAVERSE trial — the largest cardiovascular safety trial for TRT to date (5,246 men) — demonstrated that testosterone treatment was noninferior to placebo for major adverse cardiovascular events in men at elevated cardiovascular risk (Lincoff et al., 2023). The Corona et al. meta-analysis of 75 RCTs similarly found no increased cardiovascular risk with TRT (Corona et al., 2017). Earlier observational studies that suggested cardiovascular harm had significant methodological limitations. The primary cardiovascular risk associated with TRT is erythrocytosis (elevated hematocrit), which increases thrombotic risk and requires monitoring.

Question: Will I be on TRT forever?

Answer: This depends on the underlying cause of hypogonadism. For men with primary hypogonadism (testicular failure — e.g., Klinefelter syndrome, bilateral orchiectomy), TRT is typically lifelong because the testes cannot produce sufficient testosterone. For men with secondary hypogonadism from reversible causes (obesity, opioid use, sleep deprivation, excessive alcohol), addressing the underlying cause may restore endogenous production, potentially allowing TRT discontinuation. For age-related decline, endogenous recovery after discontinuation is variable — some men recover baseline production within months, while others experience prolonged suppression. The decision to continue or discontinue TRT is individualized and should be made with a healthcare provider.

Question: Is TRT the same as anabolic steroid abuse?

Answer: TRT at physiological replacement doses (targeting 400–700 ng/dL) is fundamentally different from anabolic steroid abuse. Illicit anabolic steroid use typically involves doses 5–40 times higher than TRT, often using multiple compounds simultaneously ("stacking"), and targets supraphysiological levels far above the normal range. TRT aims to restore normal levels under medical supervision with regular monitoring. The side effect profile, health risks, and clinical context are entirely different. That said, testosterone is the same molecule — the distinction is in dose, intent, medical oversight, and monitoring.

Question: Does TRT shrink the testes?

Answer: Testicular atrophy is a common and expected side effect of TRT. Exogenous testosterone suppresses LH production, which reduces Leydig cell stimulation and intratesticular testosterone. Without this stimulation, testicular volume decreases — typically by 10–25%. This is generally reversible after TRT discontinuation, though recovery may take months. HCG co-therapy (500–1,000 IU, 2–3 times per week) maintains intratesticular testosterone and preserves testicular volume during TRT.

Question: Can women take testosterone?

Answer: Testosterone therapy in women has a growing evidence base, particularly for hypoactive sexual desire disorder (HSDD) in postmenopausal women. The Davis et al. global consensus statement reviewed the evidence and concluded that low-dose testosterone (producing female-physiological levels) consistently improved sexual desire and function (Davis et al., 2019). Doses used in women are approximately one-tenth of male TRT doses. No testosterone product is FDA-approved for women, and all prescribing is off-label. Monitoring for androgenic side effects (acne, hirsutism, voice deepening, clitoromegaly) is essential.

Question: Does TRT make you aggressive or cause "roid rage"?

Answer: At physiological replacement doses, TRT does not produce the aggression or dramatic mood disturbances associated with supraphysiological anabolic steroid use. The TTrials and other controlled studies showed modest improvements in mood and reductions in irritability and depressive symptoms with TRT (Snyder et al., 2016). Some individuals report mild irritability, particularly with formulations that produce significant peak-to-trough fluctuations. Stable-level protocols (gels, twice-weekly injections) tend to produce the most consistent mood effects.

Question: Will TRT make me infertile permanently?

Answer: TRT suppresses spermatogenesis, but this is generally reversible after discontinuation. Most men recover sperm production within 6–12 months of stopping TRT, though recovery can take up to 24 months in some cases. However, full recovery is not guaranteed — a small percentage of men may have persistent oligospermia or azoospermia after prolonged TRT use. HCG co-therapy during TRT significantly improves the likelihood of maintaining fertility. Men who wish to preserve fertility should discuss this with their provider before initiating TRT.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• TRT is a well-established medical treatment for male hypogonadism, with multiple FDA-approved formulations and a robust evidence base from randomized controlled trials.
• The Testosterone Trials (TTrials) demonstrated improvements in sexual function, vitality, bone density, and anemia correction in older men with low testosterone.
• Cardiovascular safety has been substantiated by the TRAVERSE trial (5,246 men) and meta-analyses showing no increased risk of major adverse cardiovascular events with TRT.
• TRT does not appear to increase prostate cancer risk based on current evidence, though PSA monitoring remains standard. The saturation model provides a mechanistic explanation for why restoring physiological testosterone does not stimulate prostate growth.
• Fertility suppression is the most significant clinical concern for men of reproductive age. TRT suppresses spermatogenesis, and men planning to conceive should use HCG co-therapy or consider alternative treatments (clomiphene, enclomiphene).
• Injectable testosterone cypionate and enanthate represent the most cost-effective formulations ($30–$80/month), while gels, patches, pellets, and oral formulations offer convenience at higher cost.
• Ongoing monitoring is required: CBC (hematocrit), PSA, estradiol, and lipid panel every 3–6 months ensure safe therapy.
• Women's testosterone therapy has a growing evidence base for sexual dysfunction, with doses approximately one-tenth of male TRT doses. No product is FDA-approved for women.
• TRT is a Schedule III controlled substance requiring a prescription from a licensed provider with DEA registration.

Questions to Ask a Provider

• What is my total and free testosterone level, and were both measurements taken as morning blood draws?
• What is the likely cause of my low testosterone — primary, secondary, or age-related?
• Which formulation is most appropriate for my lifestyle, budget, and medical history?
• Am I planning to have children, and if so, what fertility-preserving strategy should we use?
• What monitoring schedule will we follow, and what are the key lab values to track?
• What are realistic expectations for symptom improvement, and over what timeline?
• Are there lifestyle modifications (weight loss, sleep optimization, exercise) that might improve my testosterone levels without TRT?
• What are the risks of long-term TRT in my specific clinical situation?

Sources & Further Reading

Landmark Clinical Trials

• Snyder PJ, Bhasin S, Cunningham GR, et al. (2016) — "Effects of Testosterone Treatment in Older Men" — New England Journal of Medicine
• Lincoff AM, Bhasin S, Flevaris P, et al. (2023) — "Cardiovascular Safety of Testosterone-Replacement Therapy" (TRAVERSE trial) — New England Journal of Medicine

Dose-Response and Physiology

• Bhasin S, Brito JP, Cunningham GR, et al. (2018) — "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline" — Journal of Clinical Endocrinology & Metabolism
• Harman SM, Metter EJ, Tobin JD, et al. (2001) — "Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels" — Journal of Clinical Endocrinology & Metabolism

Cardiovascular Safety

• Corona G, Rastrelli G, Di Pasquale G, et al. (2017) — "Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies" — Journal of Sexual Medicine
• Lincoff AM, et al. (2023) — TRAVERSE trial — NEJM

Prostate Safety

• Morgentaler A (2006) — "Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth" — European Urology

Women and Testosterone

• Davis SR, Baber R, Panay N, et al. (2019) — "Global Consensus Position Statement on the Use of Testosterone Therapy for Women" — Journal of Clinical Endocrinology & Metabolism

Clinical Guidelines

• Mulhall JP, Trost LW, Brannigan RE, et al. (2018) — "Evaluation and Management of Testosterone Deficiency: AUA Guideline" — Journal of Urology

Regulatory & Classification

• FDA Drug Safety Communication: Testosterone Products
• WADA: Prohibited List — S1 Anabolic Agents
• DEA: Controlled Substances Schedules

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.